84 related articles for article (PubMed ID: 12645297)
21. Bradykinin and renal fibrosis: have we ACE'd it?
Bascands JL; Schanstra JP
J Am Soc Nephrol; 2004 Sep; 15(9):2504-6. PubMed ID: 15340002
[No Abstract] [Full Text] [Related]
22. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
23. [Renoprotective effects of antihypertensives].
Monhart V
Vnitr Lek; 2004 Jul; 50(7):531-6. PubMed ID: 15323261
[TBL] [Abstract][Full Text] [Related]
24. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
Ji Z; Huang C; Liang C; Chen B; Chen S; Sun W
Cell Mol Immunol; 2005 Apr; 2(2):150-4. PubMed ID: 16191423
[TBL] [Abstract][Full Text] [Related]
25. [Inflammatory mechanisms of renal fibrosis: glomerulonephritis].
Baud L; Fouqueray B; Bellocq A
Bull Acad Natl Med; 1999; 183(1):23-31. PubMed ID: 10371762
[TBL] [Abstract][Full Text] [Related]
26. The emerging role of angiotensin-converting enzyme-2 in the kidney.
Burns KD
Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):116-21. PubMed ID: 17293686
[TBL] [Abstract][Full Text] [Related]
27. How renal cytokines and growth factors contribute to renal disease progression.
Benigni A; Remuzzi G
Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S21-4. PubMed ID: 11158856
[TBL] [Abstract][Full Text] [Related]
28. Renal ischemia modified by an angiotensin antagonist.
Uehling D; Heber D; Goodfriend TL
Invest Urol; 1974 Mar; 11(5):345-6. PubMed ID: 4361088
[No Abstract] [Full Text] [Related]
29. Opportunities for the discovery of novel therapies for fibrotic diseases.
Franklin TJ
Exp Nephrol; 1995; 3(2):143-7. PubMed ID: 7773637
[No Abstract] [Full Text] [Related]
30. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases.
Luft FC
Curr Opin Nephrol Hypertens; 2002 Jan; 11(1):59-66. PubMed ID: 11753088
[TBL] [Abstract][Full Text] [Related]
31. Effects of angiotensin-converting-enzyme inhibitors on progression to end-stage renal failure in chronic vascular rejection.
Rustom R; Paraoan MT; Sells RA; Jackson MJ; Hammad A; Bakran A; Brown M; Ahmad RA; Williams PS; Bell GM; Sharma A; Bone JM
Transplant Proc; 2001; 33(1-2):1175-6. PubMed ID: 11267244
[No Abstract] [Full Text] [Related]
32. [Pathophysiology of kidney disease progression].
Krummel T; Bazin D; Hannedouche T
Presse Med; 2007 Dec; 36(12 Pt 2):1835-41. PubMed ID: 17656061
[TBL] [Abstract][Full Text] [Related]
33. Endothelin, renal diseases, and hypertension.
Dussaule JC; Boffa JJ; Tharaux PL; Fakhouri F; Ardaillou R; Chatziantoniou C
Adv Nephrol Necker Hosp; 2000; 30():281-303. PubMed ID: 11068648
[No Abstract] [Full Text] [Related]
34. [Oral sorbent].
Niwa T
Nihon Rinsho; 2004 May; 62 Suppl 5():374-8. PubMed ID: 15197948
[No Abstract] [Full Text] [Related]
35. Fibrosis causes progressive kidney failure.
Cohen EP
Med Hypotheses; 1995 Nov; 45(5):459-62. PubMed ID: 8748086
[TBL] [Abstract][Full Text] [Related]
36. Experimental strategies to reverse chronic renal disease.
Zeisberg M; Kalluri R
Blood Purif; 2004; 22(5):440-5. PubMed ID: 15359103
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin-converting enzyme inhibitors in nondiabetic renal disease.
Colindres RE; Kshirsagar AV
Ann Intern Med; 1998 Apr; 128(8):694-5. PubMed ID: 9537948
[No Abstract] [Full Text] [Related]
38. Therapeutic strategies to halt renal fibrosis.
Yu L; Noble NA; Border WA
Curr Opin Pharmacol; 2002 Apr; 2(2):177-81. PubMed ID: 11950630
[TBL] [Abstract][Full Text] [Related]
39. [Use of tetracyclines during renal failure].
Whelton A
Nouv Presse Med; 1980 Jan; 9(21 Suppl):86-92. PubMed ID: 7355092
[No Abstract] [Full Text] [Related]
40. Renal pathophysiology.
Curr Opin Nephrol Hypertens; 1997 Jul; 6(4):B119-25. PubMed ID: 9263695
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
